TRIS PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.trispharma.com
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06545097
- Locations
- 🇺🇸
ALLEVIATE 1 Site 001106, Little Rock, Arkansas, United States
🇺🇸ALLEVIATE 1 Site 001110, Bellaire, Texas, United States
🇺🇸ALLEVIATE 1 Site 001112, Miami, Florida, United States
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06453265
- Locations
- 🇺🇸
Ohio Clinical Trials, Inc., Columbus, Ohio, United States
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT06423703
- Locations
- 🇺🇸
Alleviate 2 001113, Houston, Texas, United States
🇺🇸ALLEVIATE 2 Site 001111, San Antonio, Texas, United States
🇺🇸ALLEVIATE 2 Site 001108, Sheffield, Alabama, United States
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05491785
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, Netherlands
🇳🇱Leiden University Medical Centre (LUMC), Leiden, Netherlands
Assessment of Abuse Potential of Cebranopadol in Humans
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05256108
- Locations
- 🇺🇸
Ohio Clinical Trials, Columbus, Ohio, United States
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04027361
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03958123
- Locations
- 🇺🇸
US001 Contract research organization, West Bend, Wisconsin, United States
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03882762
- Locations
- 🇺🇸
US0002 Contract research organization, Orlando, Florida, United States
🇺🇸US0001 Contract research organization, Miami, Florida, United States
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03834766
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States
🇺🇸Meridien Research, Bradenton, Florida, United States
🇺🇸Meridien Research, Inc., Maitland, Florida, United States
A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT03757559
- Locations
- 🇨🇦
INC Research, Toronto, Ontario, Canada